Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

196 results about "Solid cancer" patented technology

Solid cancer. Definition: Solid cancers are defined as abnormal cellular growths in "solid" organs such as the breast or prostate, as opposed to leukemia, a cancer affecting the blood, which is liquid. Source: GreenFacts.

Radiolabeled FAP-alpha-affinity compound and use thereof

It is an object of the present invention to provide drugs that bind specifically to FAPα, are effective in the treatment and diagnosis of tumors or cancers expressing FAPα, for example, in the treatment and diagnosis of solid cancers such as pancreatic cancer, sarcoma, esophageal cancer, lung cancer, breast cancer, prostate cancer, head and neck cancer, ovarian cancer, colon cancer, neuroendocrine tumor, thyroid cancer, uterine cancer, liver cancer and the like (particularly, pancreatic cancer), and have a lower risk of prolonged side effects. The present invention provides a conjugate comprising a radioactive moiety comprising an aryl group substituted with a radionuclide selected from 211At, 210At, 131I, 125I, 124I, 123I, 77Br and 76Br, and a bioactive moiety having an affinity for fibroblast activation protein α (FAPα).
Owner:OSAKA UNIVERSITY

Method of treating cancers with alkyne substituted quinazoline derivatives

The present disclosure relates to methods of treating or preventing cancer (e.g., advanced solid cancer) using Compound No. 1: (Compound No. 1) or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.
Owner:BLACK DIAMOND THERAPEUTICS INC

An antibody-drug conjugate treatment of cancer

Provided herein are methods, dosage regimens, and administration of an antibody drug conjugate (ADC) for treating cancer. More specifically, the cancer is advanced or metastatic solid cancer.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Owner:CURASIGHT APS

Thermo-responsive hydrogel for intratumoral administration as a treatment in solid tumor cancers

A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl β-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.
Owner:ROYAL COLLEGE OF SURGEONS & IRELAND

Salivary sialic acid testing for cancer detection

The present systems and methods relate to devices, methods, and systems for detecting the probability of cancer conditions using Sialic Acid concentrations. The present invention relates to a non-invasive system with diagnostic and treatment capacities that use a unified code that is intrinsic to physiological brain function. Embodiments may provide salivary sialic acid testing for cancer detection, for example, breast and oral cancers. Findings indicate the effectiveness of salivary sialic acid testing for detecting solid cancers, potentially serving as an initial screening tool in laboratory settings before invasive diagnostic procedures are recommended.
Owner:GENESIS INTELLIGENCE LLC

Method for using the t cell repertoire as a predictive and prognostic biomarker in cancer

The present invention relates to a method of establishing a prediction regarding the development of a type of solid cancer in an individual, comprising: (i) collecting a biological sample that includes lymphocytes of said individual, (ii) sequencing, using NGS techniques, the mRNA associated with the V(D)J regions of the TCRs of the lymphocytes collected in the previous step, (iii) removing from the TOR repertoire obtained in the previous step the TOR sequences that are specific to other diseases than said solid cancer, (iv) using artificial intelligence algorithms to compute a predictive score for the probability that said TOR repertoire is specific for said type of cancer and (v) based on said predictive score determining the probability of said individual of developing said type of solid cancer.
Owner:FRONTIER MANAGEMENT CONSULTING SRL +1

Analogues of pentamidine and uses therefor

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.
Owner:AURANSA INC

Therapeutic agent for PARP inhibitor-resistant cancer

To provide a therapeutic agent for PARP inhibitor-resistant cancer.SOLUTION: The present invention relates to a pharmaceutical composition for treating or preventing a solid cancer patient having resistance to a PARP inhibitor, and the pharmaceutical composition according to the present invention can effectively reduce the size of a tumor in a patient having resistance to a PARP inhibitor.SELECTED DRAWING: Figure 4
Owner:ONCONIC THERAPEUTICS INC

BMP1 and PD-1 combined inhibition immunotherapy

Methods of improving PD-1 based immunotherapy in a subject suffering from a solid cancer, comprising decreasing bone morphogenetic protein 1 (BMP1) levels or function in T cells or in a tumor microenvironment (TME) or extracellular matrix (ECM) of the solid cancer are provided. Methods of treating a solid cancer comprising administering a PD-1 based immunotherapy and decreasing BMP1 levels or function in T cells or a TME or ECM of the solid cancer are also provided. Antibody drug conjugates comprising an anti-PDl blocking antibody and a BMP1 inhibiting small molecule or antibody or antigen binding fragment thereof small molecule inhibitor and pharmaceutical compositions for use in the methods of the invention are also provided.
Owner:TECHNION RES & DEV FOUND LTD

Use of paclitaxel cationic liposomes for treating tumors - Patent Application 20070122997

The present invention provides a use of paclitaxel cationic liposomes in the manufacture of a medicament for treating terminal solid cancer, a use of paclitaxel cationic liposomes and a systemic therapeutic agent in the manufacture of a medicament for treating terminal solid cancer, and a method for treating terminal solid cancer, in which a therapeutically effective amount of paclitaxel cationic liposomes is administered to a patient with terminal solid cancer, or a therapeutically effective amount of paclitaxel cationic liposomes and a systemic therapeutic agent is administered to a patient with terminal solid cancer.
Owner:CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD

Cancer vaccine composition comprising calcium lactate as active ingredient and use thereof

The present invention relates to a pharmaceutical composition comprising, as active ingredients: a) calcium lactate; and b) at least one substance selected from the group consisting of a phosphate, stem cell, cytokine, cancer cell line, antigen derived from the cancer cell line, polynucleotide encoding the antigen, antigen gene construct in which the polynucleotide is operably linked to a promoter, and expression vector comprising the gene construct. The composition of the present invention has an anti-tumor immunological memory effect, induces apoptosis of cancer cells, and thus can be used as an effective immunotherapy candidate for solid cancers, a vaccine candidate for in-situ treatment of solid cancers, and a cancer-treating agent administered into tumors.
Owner:METIMEDI PHARMA CO LTD

Anti-beta-catenin antibodies

The present disclosure relates to antibodies against beta-catenin and formulations comprising the antibodies. The present disclosure also relates to the use of beta-catenin antibodies and formulations in therapy, in particular in the treatment of solid cancer.
Owner:UCB BIOPHARMA SPRL

Pharmaceutical composition for treating cancer comprising FOXM1 mutant or FOXM1 shrna

The present invention relates to a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting growth, migration and invasion of cancer cells. In addition, it relates to a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting malignancy in a tumor microenvironment by inhibiting polarization into tumor-associated macrophages in a tumor microenvironment. It relates to a use as an apoptotic inducer using the action of sensitively inhibiting cancer cell death in metastatic cancer cells as well as general solid cancers.
Owner:IND UNIV COOP FOUND HANYANG UNIV ERICA CAMPUS

Chimeric antigen receptor targeting PD-l1 and t cell therapeutic agent expressing same

The present invention relates to a chimeric antigen receptor (CAR) binding to PD-L1 of tumor cells and a composition for treating cancer using T cells transformed with an anti-PD-L1 CAR and provides T cells expressing a chimeric antigen receptor binding specifically to PD-L1 overexpressed in various solid cancers. Moreover, in the present invention, T cells are provided with a means capable of selectively expressing a cytokine increasing anticancer efficacy together with a site encoding an anti-PD-L1 chimeric antigen receptor. In addition, the present invention provides a cell therapeutic composition for preventing or treating cancer, the composition comprising T cells expressing the anti-PD-L1 chimeric antigen receptor prepared according to the present invention.
Owner:AJOU UNIV IND ACADEMIC COOP FOUND

Treatment of solid cancer with lasofoxifene

PCT designated stage expiredWO2025043004A1Antibody ingredientsImmunoglobulinsPharmaceutical drugOncology
The disclosure provides methods of treating cancer, such as an estrogen receptor negative (ER–) solid cancer or estrogen receptor-low (ERlow) solid cancer in a patient. The method may include administering to the patient an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof.
Owner:DUKE UNIV

Analogues of pentamidine and uses therefor

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.
Owner:AURANSA INC

Affinity specifically binding to CD137 and application thereof

The present invention relates to: an affinity that specifically binds to the extracellular domain of CD137; a protein complex comprising the affinity and an antibody or an antigen-binding fragment thereof that specifically binds to a protein on the surface of cancer cells; and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. When using the affinity that specifically binds to CD137 according to the present invention, it is possible to develop a protein complex that specifically binds to antigens on the surfaces of various cancer cells while specifically binding to T cells, and thus can be effectively used in the prevention or treatment of leukemia and solid cancers.
Owner:ABCLON

Proton beam treatment composition

The present invention belongs to the field of cancer therapy, specifically relates to a proton beam therapeutic composition, and more specifically relates to a proton beam therapeutic composition comprising a chemotactic factor and an alarm element. The present invention provides a proton beam therapeutic composition comprising: a first reagent combination wherein the first reagent combination comprises a chemotactic factor and an alarm element. The composition provided by the invention can assist in proton beam anti-cancer treatment, and not only can generate a remarkable inhibition effect on solid cancer proliferation, but also can prevent cancer cells of solid cancer from distant metastasis.
Owner:CHINA INSTITUTE OF ATOMIC ENERGY

BIOMARKER FOR TREATMENT OF SOLID CANCER WITH IMIDAZO[4,5-b]PYRIDINE DERIVATIVE

Provided is a means to predict the anticancer therapeutic efficacy of 1-((5-(1R)-1-fluoroethyl)-1,3,4-oxadiazol-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine or a derivative thereof in solid cancer and thereby specifying a subject who will be the most benefitted from treatment with the compound and treatment with the compound in combination with another drug and / or another therapy. As a biomarker for predicting therapeutic response to the compound, a genetic character predicted to impart sensitivity to CLK inhibition is used.
Owner:NATIONAL CANCER CENTER(JP) +1

CD38 modulating antibody

To provide anti-CD38 antibodies that may be used in the treatment of cancer, particularly solid and hematological cancers.SOLUTION: Provided is an anti-CD38 antibody having a particular sequence, or antigen-binding fragment thereof, the anti-CD38 antibody or antigen-binding fragment thereof exhibiting antibody-dependent cell-mediated cytotoxicity (ADCC) activity against CD38+ target cells, exhibiting no complement dependent cytotoxicity (CDC) or reduced CDC activity against CD38+ target cells as compared to Daratumumab under the same or substantially the same conditions, and inducing immune effector cell activation.SELECTED DRAWING: Figure 20
Owner:BLACK BELT THERAPEUTICS LTD

Anti-cancer viruses co-expressing CD55 and CD59

The present invention relates to anti-cancer viruses that co-express complement regulatory proteins CD55 and CD59. Since the anti-cancer virus of the present invention can maintain its curative effect even when intravenously injected, the anti-cancer virus can also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. Furthermore, the anti-cancer virus of the present invention obtains resistance to attacks of an in-vivo complement system by expressing complement regulatory protein on the surface of the virus, thereby being stable in blood and maintaining stable anti-cancer activity during intravenous injection, thereby reducing the application amount of the virus to reduce the side effects of anti-cancer drugs as much as possible. Therefore, the anti-cancer virus of the present invention can be used for preventing or treating cancer.
Owner:NEW ROGER CO LTD

Delivery of therapeutic proteins

The present invention relates to the treatment of diseases associated with inflammation including solid cancers. More particularly, certain methods relate to the administration (e.g., intravenously) of polyhedrin protein (PODS) crystals for the delivery of one or more therapeutic proteins. This enables targeted release of low doses of the therapeutic protein at sites of the disease.
Owner:CELL GUIDANCE SYST LTD

Human anti-ANTXR chimeric antigen receptor and its use

The present invention relates to a chimeric antigen receptor having a ligand that specifically targets anthrax toxin receptor (ANTXR), and more specifically, to: a nucleic acid encoding a chimeric antigen receptor, the chimeric antigen receptor comprising a ligand PA63 that specifically binds to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2); a vector comprising a nucleic acid encoding a chimeric antigen receptor; and a recombinant cell comprising the vector; a pharmaceutical composition comprising the recombinant cell for preventing or treating solid cancer; and a method of treatment. Solid cancer can be treated using anti-ANTXR chimeric antigen receptor (CAR)-T cells according to the present invention, and since chimeric antigen receptor (CAR)-T cells are administered to solid cancer patients, particularly pancreatic cancer patients, for whom anticancer drug administration is ineffective, drug administration is limited, and efficient and safe customized solid cancer prevention or treatment is possible.
Owner:MJCELL BIO CO LTD